Evidence map›Paper›PMID 42767771›Full record

GuidelineJournal for immunotherapy of cancer2026

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0.

Nirali N Shah, Charles Craddock, Lia Gore, Monica L Guzman, Elias Jabbour, Alexandra R Lovell, Katia Luciani, Ravindra Majeti, Shannon L Maude, Miguel-Angel Perales and 9 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Nirali N ShahPediatric Oncology Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland, USA Nirali.Shah@som.umaryland.edu.ORCID http://orcid.org/0000-0002-8474-9080
Charles CraddockClinical Trials Unit, University of Warwick, Coventry, UK.
Lia GoreDepartment of Pediatrics, University of Colorado and Children's Hospital Colorado, Aurora, Colorado, USA.
Monica L GuzmanDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-9262-8246
Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Alexandra R LovellDivision of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Katia LucianiUniversity of Ottawa, Ottawa, Ontario, Canada.
Ravindra MajetiDepartment of Medicine, Division of Hematology, Stanford University, Palo Alto, California, USA.ORCID http://orcid.org/0000-0002-5814-0984
Shannon L MaudeDivision of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID http://orcid.org/0000-0003-2210-8736
Miguel-Angel PeralesAdult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael A PulsipherPediatric Hematology/Oncology, Intermountain Primary Children's Hospital/Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, Utah, USA.
David A SallmanDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, USA.
Bijal D ShahDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, USA.ORCID http://orcid.org/0000-0003-4328-6021
Wendy StockThe University of Chicago, Chicago, Illinois, USA.
Marion SubkleweMed. Klinik und Poliklinik III, LMU - Klinikum der Universität München, Munich, Germany.ORCID http://orcid.org/0000-0001-9154-9469
Sarah K TasianDivision of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID http://orcid.org/0000-0003-1327-1662
Brent L WoodPathology and Laboratory Medicine, Children's Hospital of Los Angeles, Los Angeles, California, USA.
Bonnie YatesPediatric Oncology Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland, USA.
Naval DaverDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute leukemia is a hematologic malignancy that affects people of all ages. Immunotherapies, including T-cell engagers, antibody-drug conjugates, and chimeric antigen receptor T-cell therapies have contributed to a paradigm shift in the treatment of patients with acute leukemia. Combined with advancements in allogeneic hematopoietic stem cell transplant and targeted therapy development, patients with acute leukemia have additional effective treatment options, providing the possibility of long-term remission. However, these advances have resulted in a complex and dynamic treatment landscape for clinicians to navigate. To guide the oncology community and provide a framework for patient care, the Society for Immunotherapy of Cancer convened a panel of experts to develop this clinical practice guideline on immunotherapy for the treatment of acute leukemia. Drawing from published data and clinical experience, the Expert Panel developed evidence-based and consensus-based recommendations relating to diagnostics; immunotherapies for the treatment of acute lymphoblastic leukemia, acute myeloid leukemia, and blastic plasmacytoid dendritic cell neoplasm; toxicity and safety management; treatment sequencing; and patient education and quality of life.

Indexed as

ImmunotherapyLeukemiaLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaHumansAntibody-drug conjugates - ADCBispecific T cell engager - BiTEChimeric antigen receptor - CAREducationLeukemia

Identifiers

PMID42767771
PMCPMC13599912

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.